Roivant Sciences Ltd's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Roivant Sciences Ltd's ROI in the first quarter of 2026?
Roivant Sciences Ltd recorded a cumulative net loss of $-415 million during 12 months ending in the first quarter of 2026, resulting in a negative return on investment (ROI) of -7.19%.

Within the Healthcare sector 167 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the fourth quarter of 2025 from 2547 to 2964.

Definition and Formula of Return on Investment

Select the Comparisons :

None ▼

Select the Ratio:

Return on Investment ROI▼

None ▼

Return on Investment ROI▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Investment	(Jun 30 2026) I. Quarter	(Mar 31 2026) IV. Quarter	(Dec 31 2025) III. Quarter	(Sep 30 2025) II. Quarter	(Jun 30 2025) I. Quarter
Y / Y Investment Change TTM	-6.58 %	-12.67 %	-19.34 %	-13.79 %	3.22 %
Y / Y Net Income Change TTM	-	-	-	-	-
Investment (TTM) in Millions	5,713	6,192	5,787	5,372	5,389
Return On Investment (TTM)	-7.19 %	-7 %	-18.02 %	-9.58 %	-11.15 %
ROIV's Overall Ranking	# 2964	# 2547	# 2941	# 2735	# 2822
Seq. Investment Change TTM	1.43 %	1.81 %	-6.87 %	-2.86 %	-5.19 %
Seq. Net Income Change TTM	-	-	-	-	-
Net Income (TTM) in Millions	-415	-398	-1,006	-574	-688

ROIV Company Profile >> Back to ROIV Roi Comparisons >> See Annual ROIV Return On Investment

Return On Investment ROIV's Ranking
Within:	No.
Industry	# 54
Sector	# 168
Overall	# 2964

Return On Investment Statistics
High	Average	Low
119.08 %	-4 %	-57.02 %
(Dec 31 2023)		(Dec 31 2022)

Financial Statements
Roivant Sciences Ltd's I. Quarter Investments	$ 5,713 Millions	ROIV's Balance sheet
Roivant Sciences Ltd's I. Quarter Income	$ -291 Millions	Quarterly ROIV's Income Statement
ROIV's Income by Division		See ROIV's Income by Division

ROIV Annual Return On Investment	(Mar 31 2026) 2025	(Mar 31 2025) 2024	(Mar 31 2024) 2023	(Mar 31 2022) 2022
Total Investments in Millions	6,192	5,787	7,436	2,401	0
Y / Y Investment Growth	7 %	-22.17 %	209.72 %	-	-
Net Income in Millions	-398	-357	4,231	-924	0
Y / Y Net Income Growth	-	-	-	-	-
Annual Return On Investment	-6.43 %	-6.16 %	56.9 %	-38.49 %	-

Annual Roi Comment

Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
ROIV's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for ROIV's Competitors
Subscribers only: Roi for Roivant Sciences Ltd's Suppliers
Subscribers only: Return On Investment for ROIV's Customers

Other Ratios
ROIV's Roa	ROIV's Inventory Turnover Ratio	ROIV's Growth Rates	ROIV's Dividend Statistics
	ROIV's Profitability Ratios	ROIV's Asset Turnover Ratio	ROIV's Dividend Growth
ROIV's Roe	ROIV's Valuation Ratios	ROIV's Financial Strength Ratios	ROIV's Dividend Payout Ratio

Companies with similar Return On Investment at Jun 30 2026, within Healthcare Sector

ROI

Date modified: 2026-09-26T07:40:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.